+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects

Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects

Pharmacopsychiatry 28(3): 93-94

Fluvoxamine belongs to the class of selective serotonin reuptake inhibitors (SSRIs) which have recently gained large popularity as antidepressant agents essentially because they lack the most troublesome adverse effects of older antidepressants (i.e. tricyclic antidepressants) such as anticholinergic effects and cardiotoxicity. Recent studies in the literature suggest that HIV-1 infected subjects are affected by depressive episodes with a relatively high frequency, often requiring an antidepressant treatment. Due to its favorable adverse effects profile, we used fluvoxamine as first line treatment for sixteen depressed HIV-1 infected subjects. They were administered the drug at a daily dosage of 100 mg in the evening. Fluvoxamine provided a good clinical efficacy for six of these patients, whereas the other ten had to discontinue the drug because of the presence of severe adverse effects such as acute total insomnia, gastro-intestinal disturbances together with anorexia, aggressive and impulsive behavior and excessive sedation. The observed fluvoxamine side-effects are not typical or specific for this particular patient group since they are also described in seronegative subjects taking fluvoxamine; however, our findings seem to indicate that they become more frequent and more severe when the drug is administered to HIV-1 infected patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 009108708

Download citation: RISBibTeXText

PMID: 7568371

DOI: 10.1055/s-2007-979597

Related references

Postherpetic neuralgia alleviated by an SSRI fluvoxamine: two cases of PHN accompanied with depression were treated with fluvoxamine. Nihon Shinkei Seishin Yakurigaku Zasshi 24(2): 79-81, 2004

Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatrica Scandinavica 78(6): 668-675, 1988

Fluvoxamine (fevarin) in the treatment of depression. Zhurnal Nevrologii i Psikhiatrii Imeni Srsakova. 2000; 100(12): 64-67, 2000

Fluvoxamine alone in the treatment of delusional depression. American Journal of Psychiatry 153(3): 414-416, 1996

Fluvoxamine (fevarin) in the treatment of depression. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 100(12): 64-67, 2001

Efficacy of fluvoxamine in treatment-refractory depression. Journal of Affective Disorders 15(1): 55-60, 1988

Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatric Journal of the University of Ottawa 15(3): 156-158, 1990

Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects. Journal of Alternative and Complementary Medicine 19(4): 334-340, 2013

A comparison of fluvoxamine and fluoxetine in the treatment of major depression. Journal of Clinical Psychopharmacology 16(5): 373-378, 1996

Fluvoxamine treatment of major depression associated with multiple sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences 16(3): 364-366, 2004

Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. International Journal of Psychiatry in Clinical Practice 11(3): 233-238, 2007

Fluvoxamine for the treatment of depression and parkinsonism in progressive supranuclear palsy. International Journal of Psychiatry in Clinical Practice 6(1): 45-47, 2002

Successful treatment of steroid-induced depression with low dosage of fluvoxamine. Australian and New Zealand Journal of Psychiatry 35(6): 855-856, 2002

Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 14(4): 433-445, 1999

Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology 44(3): 134-138, 2001